Tongluo Huayu formula for RVO with macular edema
Part of Eyes & vision, Heart & circulation clinical trials.
This trial tests a Chinese herbal formula (Tongluo Huayu) for people with a specific type of retinal vein occlusion (RVO) that also causes swelling in the central part of the retina (macular edema). The study aims to see if the formula helps by improving how your gut bacteria interact with your body's metabolism.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with retinal vein occlusion (a blockage in a small vein of the eye) and also have swelling in the central part of the retina (macular edema).
- You are not currently taking other similar Chinese herbs or participating in another clinical trial.
- You do not have other eye diseases such as glaucoma or new blood vessels in the iris.
- You do not have serious illnesses like rheumatism or lupus.
- You are not pregnant or breastfeeding.
- You do not have severe heart or brain disease, or very poor liver or kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares an AI with a doctor to decide if you need another anti-VEGF injection. You can join if you have wet AMD, diabetic macular edema, or retinal vein occlusion and have finished the first 3 monthly shots.
This trial tests a new medicine called SMO1 for people with vision loss and swelling in the eye caused by a blocked vein in the retina. It involves regular eye injections to see if the medicine can reduce swelling and improve vision.
This trial uses a special imaging test called OCT (optical coherence tomography) to look at the retina in people with retinal vein occlusion. It helps doctors see the swelling (macular edema) and better understand the condition.
This trial tests whether a substance called tauroursodeoxycholate (TUDCA) or a traditional Chinese medicine can help reduce swelling in the back of the eye caused by diabetes. It is for people with diabetic retinopathy and diabetic macular edema who have not had recent eye surgeries or changes in blood sugar or blood pressure control.
This study tests whether Zhuochuming®-3T&E, a new eye medicine, can reduce swelling in the macula (the center of the retina responsible for sharp vision) in people with diabetes who have never been treated for this condition before. The goal is to improve vision and prevent further vision loss.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
Hear when a new Retinal Vein Occlusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.